Crohn's disease: Ustekinumab induces rapid symptom reduction

被引：0
|
作者：
Simon, Annika
机构：
来源：
ZEITSCHRIFT FUR GASTROENTEROLOGIE | 2024年 / 62卷 / 05期
关键词：
D O I：
10.1055/a-2253-5211
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
Ustekinumab ist ein humaner monoklonaler IgG1 kappa -Antikorper gegen Interleukin (IL)-12/23 und ist zur Behandlung von Autoimmunerkrankungen wie Psoriasis und Morbus Crohn (MC) indiziert. Da die Ustekinumab-Reaktionsdynamik fur MC-PatientInnen im Rahmen der Therapieplanung meist eine besondere Rolle spielt, haben Colombel et al. diese auf Basis der Daten mehrerer MC-Studien einmal genauer betrachtet.
引用
收藏
页码：699 / 701
页数：2
相关论文
共 50 条
  • [31] EFFECTIVENESS OF USTEKINUMAB DOSE ESCALATION IN CROHN'S DISEASE
    Ollech, Jacob
    Normatov, Inessa
    Peleg, Noam
    Patel, Shivani
    Rai, Victoria
    Wang, Jingzhou D.
    Yi, Yangtian
    Singer, Jorie
    Dalal, Sushila
    Sakuraba, Atsushi
    Cohen, Russell D.
    Rubin, David T.
    Pekow, Joel R.
    GASTROENTEROLOGY, 2020, 158 (06) : S961 - S961
  • [32] Ustekinumab in the management of Crohn's disease: Expert opinion
    Armuzzi, Alessandro
    Ardizzone, Sandro
    Biancone, Livia
    Castiglione, Fabiana
    Danese, Silvio
    Gionchetti, Paolo
    Orlando, Ambrogio
    Rizzello, Fernando
    Scribano, Maria Lia
    Vecchi, Maurizio
    Daperno, Marco
    DIGESTIVE AND LIVER DISEASE, 2018, 50 (07) : 653 - 660
  • [33] A Drug Reaction to Ustekinumab in a Patient With Crohn's Disease
    Yabumoto, Maya
    Wong, Kimberly
    Parekh, Nimisha
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2020, 115 : S1202 - S1202
  • [34] An Assessment of Ustekinumab Immunogenicity in Perianal Crohn's Disease
    Manski, Scott
    Dioguardi, Vincent
    Weil, Blake J.
    Edirisuriya, Chelsea
    Shivashankar, Raina
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2023, 118 (10): : S848 - S849
  • [35] Ustekinumab intensification in Crohn's disease: a systematic review
    Gonzalez Furelos, Tania
    Sobrido Prieto, Maria
    Rodriguez Legazpi, Iria
    ARS PHARMACEUTICA, 2022, 63 (04) : 345 - 354
  • [36] Treatment of refractory cutaneous Crohn's disease with ustekinumab
    Patel, B. M.
    Rivers, C. Ramos
    Koutroumpakis, F.
    Ahsan, M.
    Dueker, J.
    Hashash, J.
    Johnston, E.
    Barrie, A.
    Harrison, J.
    Schwartz, M.
    Babichenko, D.
    Tang, G.
    Binion, D. G.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2021, 141 (05) : S72 - S72
  • [37] Ustekinumab: A Review in Moderate to Severe Crohn's Disease
    Lamb, Yvette N.
    Duggan, Sean T.
    DRUGS, 2017, 77 (10) : 1105 - 1114
  • [38] USTEKINUMAB IS SAFE IN ELDERLY CROHN'S DISEASE PATIENTS
    Garg, Rajat
    Aggarwal, Manik
    Regueiro, Miguel D.
    Click, Benjamin H.
    GASTROENTEROLOGY, 2020, 158 (06) : S447 - S448
  • [39] Ustekinumab Versus Adalimumab in Patients With Crohn's Disease
    Segal, Jonathan P.
    GASTROENTEROLOGY, 2022, 163 (04) : 1115 - 1116
  • [40] Crohn's Disease: Induction and Maintenance Therapy with Ustekinumab
    Lorenz, Judith
    ZEITSCHRIFT FUR GASTROENTEROLOGIE, 2019, 57 (01): : 14 - +
12345